Preclinical News and Research

RSS

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

PPACA program provides $733,438 grant to Inovio

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a $733,438 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).

2 Nov 2010

ISHIB releases new recommendations to manage hypertension in African Americans

Through the publication of its Consensus Statement on the Management of High Blood Pressure in Blacks in this week's issue of Hypertension, ISHIB today released new recommendations recognizing that high blood pressure among African Americans is a severe health problem. The consensus statement suggests that treatment should start sooner and be more aggressive among African Americans.

2 Nov 2010

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.

2 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

Acorda reports net income of $12.4 million for third quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2010.

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

Xstrahl launches new control system for X-ray therapy

Xstrahl, a designer and manufacturer of a world-renowned range of superficial and orthovoltage radiotherapy systems that have been essential in supporting healthcare professionals and their patients in over 500 clinics for the past 15 years, today announces the launch of Imperium, a new control system for its X-ray therapy system, at this year's ASTRO conference in San Diego, 31 October - 4 November.

From Xstrahl 1 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Researchers to investigate new drugs for parasitic disease

Urgently-needed new treatment for a parasitic disease is being investigated in research led at the University of Strathclyde in Glasgow, Scotland. Human African Trypanosomiasis, also known as sleeping sickness, affects between 50,000 and 70,000 people in Africa and South America. It is transmitted through the bite of the tsetse fly and attacks the nervous system and brain, leading to fever, headaches and disturbed sleep patterns.

30 Oct 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Compugen signs oncology research collaboration agreement with Seattle Genetics

Compugen Ltd. announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

University of Maryland to establish major research enterprise for autoimmune diseases

With a new $45 million private gift from the family of a grateful patient, the University of Maryland School of Medicine is planning to establish the nation's only major research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma and Type 1 diabetes. The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland.

29 Oct 2010

Preclinical News and Research

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

PPACA program provides $733,438 grant to Inovio

ISHIB releases new recommendations to manage hypertension in African Americans

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Acorda reports net income of $12.4 million for third quarter 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Xstrahl launches new control system for X-ray therapy

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Researchers to investigate new drugs for parasitic disease

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Merck reports $342 million net income for 2010 third quarter

Compugen signs oncology research collaboration agreement with Seattle Genetics

Novel small molecule inhibitors may provide new therapy for colon cancer

University of Maryland to establish major research enterprise for autoimmune diseases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News